Literature DB >> 30209781

I-Cell Disease (Mucolipidosis II): A Case Series from a Tertiary Paediatric Centre Reviewing the Airway and Respiratory Consequences of the Disease.

Rachel Edmiston1, Stuart Wilkinson2, Simon Jones3, Karen Tylee3, Alexander Broomfield3, Iain A Bruce4,5.   

Abstract

BACKGROUND: Inclusion cell disease (I-cell) is a rare autosomal recessive metabolic disease involving multiple organ systems, associated with a severely restricted life expectancy. No curative therapy is currently available, with management aimed at symptom palliation.
METHODS: We present a retrospective, single-centre, case series of children referred to a tertiary paediatric metabolic service. The clinical presentation, demographics, genetics and natural history of the condition are investigated.
RESULTS: Five patients with I-cell disease were referred over a 10-year period. All patients were born with dysmorphic features and had a family history of I-cell disease on further exploration. Phenotypic variation was seen within patients with the same genetic profile. Airway problems were common with 100% of the documented sleep oximetry studies suggesting sleep-disordered breathing. Of the two patients who had tracheal intubation anaesthetic difficulties we encountered, one required intraoperative reintubation, and one suffered a failed intubation with subsequent death. All five patients required oxygen therapy with the use of CPAP and BiPAP also seen. Feeding issues were almost universal with four of the five patients requiring nasogastric feeding. Four patients had died in the 10-year period with a mean life expectancy of 36 months. Cause of death for three of the four patients was respiratory failure.
CONCLUSIONS: Airway problems, including sleep-disordered breathing, were ubiquitous in this cohort of children. Any intervention requiring a general anaesthetic needs careful multidisciplinary consideration due to significant associated risks and possibly death. Management as a result is generally non-surgical and symptomatic. This case series demonstrates universal involvement of the airway and respiratory systems, an important consideration when selecting meaningful outcomes for future effectiveness studies of novel therapies.

Entities:  

Keywords:  Airway; I-cell disease; Inclusion cell; Mucolipidosis II; Respiratory disorders

Year:  2018        PMID: 30209781      PMCID: PMC6336676          DOI: 10.1007/8904_2018_130

Source DB:  PubMed          Journal:  JIMD Rep        ISSN: 2192-8304


  12 in total

1.  Nocturnal pulse oximetry as an abbreviated testing modality for pediatric obstructive sleep apnea.

Authors:  R T Brouillette; A Morielli; A Leimanis; K A Waters; R Luciano; F M Ducharme
Journal:  Pediatrics       Date:  2000-02       Impact factor: 7.124

Review 2.  Otorhinolaryngological manifestations of the mucopolysaccharidoses.

Authors:  M A Simmons; I A Bruce; S Penney; E Wraith; M P Rothera
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2005-05       Impact factor: 1.675

3.  Airway management considerations in children with I-cell disease.

Authors:  Jonathan Mallen; Mallory Highstein; Lee Smith; Jeffrey Cheng
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2015-03-07       Impact factor: 1.675

4.  A fibreoptic intubation technique for children with mucopolysaccharidoses using the laryngeal mask airway.

Authors:  R W Walker; D L Allen; M R Rothera
Journal:  Paediatr Anaesth       Date:  1997       Impact factor: 2.556

5.  I-cell disease, mucolipidosis II. Pathological, histochemical, ultrastructural and biochemical observations in four cases.

Authors:  E F Gilbert; G Dawson; G M zu Rhein; J M Opitz
Journal:  Z Kinderheilkd       Date:  1973

6.  Ultrastructure of cultured fibroblasts in I-cell disease.

Authors:  J Hanai; J Leroy; J S O'Brien
Journal:  Am J Dis Child       Date:  1971-07

7.  Improved morbidity with the use of nasal continuous positive airway pressure in I-cell disease.

Authors:  S Sheikh; K Madiraju; Q Qazi; M Rao
Journal:  Pediatr Pulmonol       Date:  1998-02

8.  Narrow trachea in mucopolysaccharidoses.

Authors:  M E Peters; S Arya; L O Langer; E F Gilbert; R Carlson; W Adkins
Journal:  Pediatr Radiol       Date:  1985

9.  Mucolipidosis II and III. The genetic relationships between two disorders of lysosomal enzyme biosynthesis.

Authors:  O T Mueller; N K Honey; L E Little; A L Miller; T B Shows
Journal:  J Clin Invest       Date:  1983-09       Impact factor: 14.808

10.  Unusual pulmonary findings in mucolipidosis II.

Authors:  Marleine Ishak; Eduardo V Zambrano; Alia Bazzy-Asaad; Americo E Esquibies
Journal:  Pediatr Pulmonol       Date:  2011-12-07
View more
  3 in total

1.  Anaesthesia-Relevant Disease Manifestations and Perianaesthetic Complications in Patients with Mucolipidosis-A Retrospective Analysis of 44 Anaesthetic Cases in 12 Patients.

Authors:  Luise Sophie Ammer; Nicole Maria Muschol; René Santer; Annika Lang; Sandra Rafaela Breyer; Phillip Brenya Sasu; Martin Petzoldt; Thorsten Dohrmann
Journal:  J Clin Med       Date:  2022-06-24       Impact factor: 4.964

2.  Placental pathology in an unsuspected case of mucolipidosis type II with secondary hyperparathyroidism in a premature infant.

Authors:  Parith Wongkittichote; Garland Michael Upchurch; Louis P Dehner; Timothy Wood; Jorge L Granadillo
Journal:  Mol Genet Metab Rep       Date:  2021-03-25

3.  GCAF(TMEM251) regulates lysosome biogenesis by activating the mannose-6-phosphate pathway.

Authors:  Weichao Zhang; Xi Yang; Yingxiang Li; Linchen Yu; Bokai Zhang; Jianchao Zhang; Woo Jung Cho; Varsha Venkatarangan; Liang Chen; Bala Bharathi Burugula; Sarah Bui; Yanzhuang Wang; Cunming Duan; Jacob O Kitzman; Ming Li
Journal:  Nat Commun       Date:  2022-09-12       Impact factor: 17.694

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.